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Abstract
Molecular imaging is used for the detection of biochemical processes through the development
of target-specific contrast agents. Separately, modalities such as nuclear and near-infrared
fluorescence (NIRF) imaging have been shown to non-invasively monitor disease. More
recently, merging of these modalities has shown promise owing to their comparable detection
sensitivity and benefited from the development of dual-labeled imaging agents. Dual-labeled
agents hold promise for whole-body and intraoperative imaging and could bridge the gap
between surgical planning and image-guided resection with a single, molecularly targeted agent.
In this review, we summarized the literature for dual-labeled antibodies and peptides that have
been developed and have highlighted key considerations for incorporating NIRF dyes into
nuclear labeling strategies. We also summarized our findings on several commercially available
NIRF dyes and offer perspectives for developing a toolkit to select the optimal NIRF dye and
radiometal combination for multimodality imaging.
Key words: Dual-labeling, Multimodality, Radiochemistry, Positron emission tomography,
Near-infrared fluorescence, Single-photon emission computed tomography
Introduction
T
he advent of molecular imaging in clinical practice
originates from radiopharmacology and is enabled by
the exquisite sensitivity of devices and tracers that remain
the “gold-standard” for molecular imaging approaches.
Recently, advances in ﬂuorescence imaging instrumentation
and probe development promise new opportunities for its
clinical implementation. As evidence of its emerging role in
clinical studies, a recent literature search on PubMed shows
that the number of papers describing the clinical use of near-
infrared ﬂuorescence (NIRF) imaging has markedly in-
creased in the past 5 years (Fig. 1). To date, all clinical
NIRF imaging studies have been restricted to indocyanine
green (ICG) [1], the only dye which is approved for
diagnostic use based upon intravenous administration for
visualization of its dark green color. Despite its limitations
as a ﬂuorescent agent, which include (1) poor ﬂuorescence
properties arising from low quantum yield (QY), (2) small
Stokes shift, (3) insufﬁcient chemical and photostability in
buffer or physiologic conditions, (4) the propensity to form
aggregates in aqueous media, and (5) lack of a functional
group for conjugation to targeting moieties, ICG has been
used intraoperatively to assess blood vessel patency, tumor-
draining lymphatics and lymph node (LN) basins, and tumor
margins (for review see [2–5]). ICG has also been used to
non-invasively detect blood and lymphatic vasculatures, as
well as LNs following microdose (i.e., 1/100 of the
pharmacologic dose, ≤100 μg of labeled protein, or ≤30 nmol
of labeled biologic agent) administration in humans [6].
Given the sensitivity demonstrated in these initial Correspondence to: Ali Azhdarinia; e-mail: ali.azhdarinia@uth.tmc.eduinvestigational human studies with ICG, new NIRF dyes
with functional groups for bioconjugation now promise
unique clinical opportunities for ﬂuorescence-guided
s u r g e r yw i t ht a r g e t e dm o l e c u l a ri m a g i n g .W h i l en u c l e a r
imaging probes enable molecularly guided resection of
tissues using audible detection, ﬂuorescence arising from
a localized targeting agent may enable real-time visual
detection and permit image-guided resection of diseased
tissues within the surgical ﬁeld of view.
The success of NIRF molecular imaging critically
depends upon demonstrating that its sensitivity for intra-
operative and non-invasive molecular imaging rivals that
offered by nuclear modalities. To provide a baseline by
which NIRF imaging can be compared to nuclear imaging
modalities, it is instructive to compare the physics of both
modalities (Fig. 2). While nuclear imaging depends upon
detecting the emission of highly penetrating gamma photons
(25–511 keV) produced in the course of radioactive decay,
NIRF depends upon the selective and repeated activation of
a ﬂuorescent dye by tissue-penetrating excitation light and
the collection of the low-energy emission photons. The
radiative decay of a radiotracer occurs only once. In contrast,
ﬂuorescent dye molecules can experience repeated activation
and radiative decay. Given a typical ﬂuorescent lifetime, or
the mean time between activation and radiative relaxation of
1 ns, and given that 10% of all relaxations typically result in
emitted radiation, the maximum photon count rate that a
single ﬂuorescent dye molecule can theoretically achieve is
100,000,000 ﬂuorescent photons/s [7]. Unfortunately, the
emitted low-energy (∼1.5 eV) photons are multiply scattered
during tissue transit, creating a tradeoff between the amount
of ﬂuorescent photons generated in deeper tissues and the
amount detected at tissue surfaces. Because attenuation of
light is minimal at tissue surfaces and subsurfaces within the
surgical ﬁeld, ﬂuorescent dyes may provide greater sensitivity
than the clinical standard of radiotracers for intraoperative
guidance; hence “ﬁrst-in-humans” NIRF molecular targeting
agents are more likely to have their initial clinical application
occur in the surgical suite.
Unlike nuclear imaging where emitted photons can be
readily detected regardless of depth, the attenuation of NIR
ﬂuorescent light emanating from deep tissues limits the
sensitivity of ﬂuorescence imaging and tomography as
compared to its more established nuclear counterpart.
Nonetheless, targeted NIRF conjugates have shown high
sensitivity for in vivo preclinical molecular imaging, permit-
ting agent administration at levels comparable to that of
radiotracers (i.e., high fM–pM of administered agent) [8],
and enabling dual-labeling strategies. Dual-labeled imaging
agents capable of (1) whole-body or regional nuclear
imaging for surgical planning, and (2) NIRF imaging for
molecularly guided surgery could improve patient outcomes
by combining capabilities for diagnostic radiology with
image-guided surgery in a single-imaging agent. Moreover,
the addition of a NIRF dye onto a radiotracer enables the
deﬁnitive correlation between the imaging used for surgical
planning and the imaging used to direct surgery. Besides
their clinical utility, dual-labeled imaging agents provide a
method to quantitatively and deﬁnitively validate preclinical
NIRF tomography using standard positron emission tomog-
raphy (PET) or single-photon emission computed tomogra-
phy (SPECT) values of percent injected dose per gram of
tissue as “ground truth” in hybrid imaging. While the co-
administration of a singly labeled nuclear and singly labeled
ﬂuorescent agent containing the same targeting moiety may
seem like a simpler strategy to achieve the clinical and
preclinical aims described above, differences in pharmaco-
kinetics (PK), binding afﬁnities, physical half-life, and the
complexities of co-administration of two distinct imaging
agents restrict practical application. Given that the physio-
logical properties of most NIRF dyes are based on organic
molecules with molecular weight (MW) ∼1,000 Da, while
typical radioisotope chelators are polar molecules 300–
400 Da (Fig. 3), it is highly unlikely that a singly labeled
nuclear and singly labeled ﬂuorescent agent will have
comparable biodistribution and pharmacokinetic properties.
Indeed, the nuclear imaging literature is replete with
examples of targeting moieties that, when labeled with
different chelators and radioisotopes, exhibit differing bio-
distribution and PK that can impact imaging performance
[9–12].
While NIRF molecular imaging has demonstrated high
sensitivity, when NIRF dyes are incorporated in a dual-
labeled format, their performance will depend critically upon
the stability and optical properties of the ﬂuorescent dye
after subjection to conditions of radiolabeling. Since most
dual-labeled agents under development undergo radiolabeling
in the ﬁnal step, factors such as radiolabeling conditions,
radiolysis, or interaction between radiometal and ﬂuorophore
must be considered. Thus, there is an urgent need for
characterizing optical properties of NIRF dyes after radio-
labelingtodeterminedual-labelingcombinationsthatarelikely
to best retain the ﬂuorescence intensity of NIRF dyes. The
recent surge of commercial NIRF dye development with
favorable optical properties, enhanced stability, and different
reactive groups for conjugation now afford numerous oppor-
tunities for probe development, but there are limited reports
Fig. 1. Number of PubMed publications per year describing
clinical NIRF studies (as of July 2011).
262 A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agentswhich compare their optical properties under conditions for
dual labeling. With the convergence of diverse radiochemistry
formulationsfor keyradiometals employedinnuclearimaging,
limited assessmentofoptical propertiesfor dual-labeledprobes
and variable sensitivity between existing NIRF imaging
systems, it is conceivable that current radiolabeling approaches
may adversely affect ﬂuorescent properties and reduce the
effectivenessofa NIRFdyeasa contrastagent.Recent reviews
have addressed dual-modality probes with various non-
invasive imaging platforms [13, 14] and multimodal tumor-
targeting peptides with ﬂuorescent and NIRF dyes [15];
however, to date, there is a paucity of information available
in the literature to guide researchers in dual-labeling schemes
that would preserve NIRF sensitivity.
In this review, we examine the compositions and
characterization of dual-labeled imaging agents and focus
on the development of chelator-based monoclonal antibody
(mAb) and peptide-targeting moieties. Herein, we limit our
analysis to dual-labeled probes possessing organic NIRF
dyes which emit at 750–900 nm, as these have agents have
the greatest potential for clinical translation, offer the lowest
background due to the lack of autoﬂuorescence at excitation
wavelengths 9750 nm, and consequently possess the greatest
sensitivity [7, 16]. Also, based on our ongoing research with
Fig. 2. a Schematic representing the physics of nuclear imaging modalities whereby upon radiative decay, high-energy
photons are emitted and detected with limited scattering effects. b Schematic representing the physics of NIRF imaging
whereby upon activation of the fluorophore by excitation light, the emitted fluorescence signal is highly scattered in tissue prior
to detection by a CCD-based camera system.
A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agents 263novel ﬂuorophores and imaging conjugates, we present new
data on the optical properties of several commercially
available NIRF dyes. Speciﬁcally, we conducted a system-
atic study on the NIRF dyes listed in Table 1 to directly
compare their optical properties in (1) water, (2) nonradio-
active labeling conditions, and (3) conventional radiolabel-
ing. We selected buffering schemes based on the most
frequently employed radiometals in dual-labeled probe
development, technetium-99m (
99mTc), indium-111 (
111In),
copper-64 (
64Cu), and gallium-68 (
68Ga), to ensure rele-
vance of the ﬁndings for both ongoing preclinical research
and future translational opportunities. Ultimately, we pro-
vide perspectives on the opportunities for multimodal
imaging in preclinical and translational research.
Dual-Labeled Imaging
Agents-mAb-Based Targeting
Full length mAbs and mAb fragments offer an excellent
approach for creating high-afﬁnity, dual-labeling imaging
agents because of (1) the high speciﬁcity for targets, (2) an
abundance of reactive amino acid residues (i.e., lysines and
cysteines) for conjugation of chelators and NIRF dyes, (3)
the plethora of therapeutic mAbs on the market and within
clinical trials, (4) the clinical acceptance of radioimmuno-
scintigraphy, and (5) the versatility of imaging agent design
offered by mAb engineering [17]. Table 2 lists the published
studies that utilize existing therapeutic monoclonal mAbs for
preclinical imaging of human epidermal growth factor
receptor-1 and 2 (HER-1, HER-2), epidermal growth factor
receptor-1 (EGFR), CD20, and epithelial cell adhesion
molecule (EpCAM), and identiﬁes the different dual-
labeling strategies and chemical compositions (i.e., selection
of chelator, NIRF dye, radiochemistry scheme, optical
characterization) employed.
Single-Photon-Emitting Agents
Trastuzumab is a therapeutic agent that targets HER-2, a disease
marker that is conserved in metastases in 30% of all breast
cancers [18] and is increasingly associated with other cancers
[19–22]. In their studies of NIRF and SPECT imaging of dual-
labeled trastuzumab in a xenograft model of breast cancer,
Sampath et al. prepared a multimodal mAb using IRDye
800CW and diethylenetriaminepentaacetic acid (DTPA) for
111In radiolabeling[23].TheirﬁndingsshowedthatplanarNIRF
images possessed similar target-to-background ratios, but
reduced noise when compared to SPECT images. Their superior
imaging qualities in the shallow tissues of animals may be a
result of the higher photon count rate of NIRF as opposed to
radioactive labels. Ogawa and colleagues targeted HER-1 and
HER-2 in an attempt to take advantage of the mutual
cooperation of nuclear and NIRF imaging through the develop-
ment of a quantitative radiolabeled probe and an activatable
optical probe [24]. The authors used mAbs dual-labeled with
111In-DTPA and an ICG analog that possessed a reactive group
for bioconjugation. In vitro microscopy demonstrated that there
was no ﬂuorescence signal with either conjugate when the
probes werebound to cell surface antigens.After internalization,
bright ﬂuorescence signal was detectable only in the target cells,
demonstrating that both conjugates work as activatable probes.
The ﬁndings were conﬁrmed by in vivo optical imaging and
similar biodistribution proﬁles were obtained with radio and
optical dual-labeled probes. In a study by Aldrich et al.,
trastuzumab was dual-labeled with IRDye 800CW and
111In-
DTPA to establish a novel, validated assay to assess the amount
of free dye in solution [25]. The authors found that the sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) method was accurate and valid for free dye detection
with applicability for other NIRF containing mAb imaging
agents where high-performance liquid chromatography (HPLC)
assessment of purity is not feasible.
Cetuximab targets EGFR overexpressed in metastatic
cancers, and is a therapeutic in metastatic colorectal and
head and neck cancers. Xu et al. developed dual-labeled
analogs of trastuzumab and cetuximab with Cy7 and
111In-
DTPA through a novel modular synthetic strategy resulting
in mAb-based imaging probe libraries [26]. They showed
strong binding to cancer cells and described potential use of
their strategy for other targeting vectors (e.g., mAbs,
afﬁbodies, and peptides) through thiol-based linkage.
PET Agents
All of the dual-labeled mAbs reported above underwent
SPECT imaging in part due to the long half-life of
111In and
its well-known chelation chemistry with DTPA. The use of
PET offers several advantages over planar scintigraphy and
SPECT including higher sensitivity (∼2–3 orders of magni-
tude) and better spatial resolution, and is increasingly used in
the clinic for the diagnosis, staging, and restaging of malignant
Fig. 3. Examples of BFCAs used for radiolabeling (MW shown).
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mAb agent to that utilizes the PET platform was by Paudyal et
al. for imaging CD20 lymphoma in mice [27]. Anti-CD20
mAbs have become the mainstay in the treatment of non-
Hodgkin’s lymphomas and have shown efﬁcacy in patients
with B-cell chronic lymphocytic leukemia. The authors used
the anti-CD20 murine mAb NuB2 for targeting CD20 positive
tumors and used the positron emitting radionuclide,
64Cu,
through the use of 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA) as the bifunctional chelating agent
(BFCA), along with Alexa Fluor 750. They were able to show
that
64Cu-DOTA-NuB2-Alexa Fluor 750 exhibits strong and
speciﬁcbindingtothetumor-expressingCD20antigenthrough
ex vivo biodistribution and in vivo PET and NIRF imaging. In
addition, there was a statistically signiﬁcant correlation
between radioactivity and ﬂuorescence intensity, conﬁrming
the stability of the dual functional probe.
Another example of a dual-labeled mAb used for PET
was given by Sampath and colleagues who developed a
dual-labeled analog of trastuzumab for PET/NIRF imaging
to detect metastatic breast cancer [28]. The authors conju-
gated
64Cu-DOTA and IRDye 800CW to the mAb and their
ﬁndings showed excellent tumor localization which beneﬁt-
ted from the increased resolution of PET compared to the
previous trastuzumab reports using
111In-SPECT. Also, the
use of PET imaging permitted improved quantiﬁcation of
tracer uptake in local and metastatic sites.
Further use of PET imaging for multimodal probe develop-
ment was shown in a study targeting EpCAM expression in
prostate cancer. Therapeutic mAbs against EpCAM are
currently in several clinical trials for the indication of
preventing metastases in patients diagnosed with various
cancers [29] and are used diagnostically for detection of
circulating tumor cells [30–32]. In a study by Hall and
colleagues, mAbs against EpCAM were dual-labeled with
IRDye 800CW and
64Cu-DOTA and provided both intra-
operative and non-invasive imaging of cancer-positive LNs in
an orthotopic model of metastatic human prostate cancer [33].
The authors found that NIRF planar imaging possessed greater
sensitivity and speciﬁcity for tumor-positive lesions than PET
imaging. Although the performance of planar imaging is not
directly comparable to tomographic imaging, these results
nonetheless provide evidence of the added utility that planar
NIRF imaging could provide to nuclear imaging modalities,
especially in intraoperative guidance.
Dual-Labeled Imaging
Agents-Peptide-Based Targeting
The growing interest in multimodal imaging has relied
heavily upon the robustness of peptide chemistry to extend
the role of existing radiopeptides to carry both a BFCA and
NIRF dye. The fact that the great majority of dual-labeled
imaging agents reported in the literature is peptide-based
attests to the versatility of peptide chemistry as a manufac-
turing platform for probe development. Table 3 provides a
H
E
R
-
2
(
t
r
a
s
t
u
z
u
m
a
b
)
D
O
T
A
I
R
D
y
e
8
0
0
C
W
C
u
-
6
4
0
.
2
M
N
H
4
O
A
c
5
.
5
5
0
°
C
,
1
h
A
d
m
i
n
i
s
t
e
r
e
d
N
G
N
G
￿
P
r
o
v
i
d
e
d
P
E
T
a
n
a
l
o
g
o
f
t
r
a
s
t
u
z
u
m
a
b
f
o
r
m
u
l
t
i
m
o
d
a
l
i
m
a
g
i
n
g
[
2
8
]
￿
A
m
o
u
n
t
:
1
n
m
o
l
￿
M
u
l
t
i
m
o
d
a
l
a
g
e
n
t
s
h
o
w
e
d
g
r
e
a
t
e
r
s
e
n
s
i
t
i
v
i
t
y
i
n
d
e
t
e
c
t
i
o
n
o
f
m
e
t
a
s
t
a
s
e
s
o
v
e
r
e
x
p
r
e
s
s
i
n
g
H
E
R
-
2
t
h
a
n
F
D
G
￿
A
c
t
i
v
i
t
y
:
5
.
6
M
B
q
E
p
C
A
M
(
m
A
b
9
6
0
1
)
D
O
T
A
I
R
D
y
e
8
0
0
C
W
C
u
-
6
4
0
.
1
N
N
a
O
A
c
6
4
0
°
C
,
1
h
P
r
e
p
a
r
e
d
N
G
N
G
￿
S
h
o
w
e
d
s
t
r
o
n
g
c
o
r
r
e
l
a
t
i
o
n
b
e
t
w
e
e
n
r
a
t
e
s
o
f
d
e
t
e
c
t
i
n
g
L
N
m
e
t
a
s
t
a
s
e
s
b
y
N
I
R
F
i
m
a
g
i
n
g
a
n
d
P
E
T
/
C
T
[
3
3
]
￿
A
m
o
u
n
t
:
6
6
7
p
m
o
l
￿
R
a
d
i
o
l
a
b
e
l
e
n
a
b
l
e
s
q
u
a
n
t
i
ﬁ
c
a
t
i
o
n
,
w
h
i
l
e
t
h
e
o
p
t
i
c
a
l
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
a
l
l
o
w
a
p
p
l
i
c
a
t
i
o
n
s
f
o
r
i
m
a
g
e
-
g
u
i
d
e
d
r
e
s
e
c
t
i
o
n
o
f
c
a
n
c
e
r
-
p
o
s
i
t
i
v
e
n
o
d
e
s
d
u
r
i
n
g
l
a
p
a
r
o
s
c
o
p
y
o
r
a
t
t
h
e
t
i
m
e
o
f
r
a
d
i
c
a
l
p
r
o
s
t
a
t
e
c
t
o
m
y
￿
A
c
t
i
v
i
t
y
:
7
4
M
B
q
￿
F
i
n
d
i
n
g
s
s
u
g
g
e
s
t
n
o
n
-
i
n
v
a
s
i
v
e
i
m
a
g
i
n
g
m
a
y
h
e
l
p
i
m
p
r
o
v
e
P
C
a
L
N
s
t
a
g
i
n
g
a
n
d
s
u
r
g
i
c
a
l
g
u
i
d
a
n
c
e
A
d
m
i
n
i
s
t
e
r
e
d
￿
A
m
o
u
n
t
:
2
6
7
–
1
,
0
0
0
p
m
o
l
￿
A
c
t
i
v
i
t
y
:
2
.
8
–
1
1
.
1
M
B
q
N
G
n
o
t
g
i
v
e
n
N
G
n
o
t
g
i
v
e
n
A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agents 267T
a
b
l
e
3
.
S
u
m
m
a
r
y
o
f
d
u
a
l
-
l
a
b
e
l
e
d
p
e
p
t
i
d
e
a
g
e
n
t
s
f
o
r
n
u
c
l
e
a
r
/
N
I
R
F
i
m
a
g
i
n
g
a
T
a
r
g
e
t
C
h
e
l
a
t
o
r
N
I
R
F
D
y
e
R
a
d
i
o
n
u
c
l
i
d
e
R
e
a
c
t
i
o
n
b
u
f
f
e
r
p
H
H
e
a
t
i
n
g
c
o
n
d
i
t
i
o
n
s
D
o
s
e
p
r
e
p
a
r
e
d
o
r
a
d
m
i
n
i
s
t
e
r
e
d
O
p
t
i
c
a
l
s
t
a
b
i
l
i
t
y
(
H
P
L
C
)
S
p
e
c
t
r
a
l
p
r
o
p
e
r
t
i
e
s
e
v
a
l
u
a
t
e
d
C
o
n
c
l
u
s
i
o
n
s
R
e
f
s
I
n
t
e
g
r
i
n
α
v
β
3
D
T
P
A
I
R
D
y
e
8
0
0
C
W
I
n
-
1
1
1
0
.
1
M
N
a
O
A
c
5
.
5
2
5
°
C
,
1
5
m
i
n
A
d
m
i
n
i
s
t
e
r
e
d
N
G
E
x
/
E
m
s
p
e
c
t
r
a
￿
P
r
o
v
i
d
e
d
a
c
o
m
p
a
r
a
t
i
v
e
a
s
s
e
s
s
m
e
n
t
o
f
o
p
t
i
c
a
l
i
n
t
e
n
s
i
ﬁ
e
d
c
h
a
r
g
e
-
c
o
u
p
l
e
d
d
e
v
i
c
e
c
a
m
e
r
a
i
m
a
g
e
i
n
c
o
m
p
a
r
i
s
o
n
w
i
t
h
n
u
c
l
e
a
r
i
m
a
g
i
n
g
[
3
7
,
6
2
]
￿
A
m
o
u
n
t
:
5
n
m
o
l
￿
S
h
o
w
e
d
o
p
t
i
c
a
l
i
m
a
g
i
n
g
i
s
h
i
g
h
l
y
s
e
n
s
i
t
i
v
e
t
o
p
h
o
t
o
n
s
e
m
a
n
a
t
i
n
g
f
r
o
m
s
u
p
e
r
ﬁ
c
i
a
l
d
e
p
t
h
s
￿
A
c
t
i
v
i
t
y
:
3
.
3
M
B
q
￿
D
e
m
o
n
s
t
r
a
t
i
o
n
o
f
f
e
a
s
i
b
i
l
i
t
y
o
f
n
u
c
l
e
a
r
/
N
I
R
F
i
m
a
g
i
n
g
w
i
t
h
a
s
i
n
g
l
e
a
g
e
n
t
a
n
d
p
r
o
p
o
s
e
d
p
a
t
h
f
o
r
t
r
a
n
s
l
a
t
i
o
n
o
f
N
I
R
ﬂ
u
o
r
e
s
c
e
n
c
e
t
h
r
o
u
g
h
d
u
a
l
-
l
a
b
e
l
i
n
g
I
n
t
e
g
r
i
n
α
v
β
3
D
F
O
C
y
p
a
t
e
C
o
l
d
G
a
,
I
n
,
C
u
W
a
t
e
r
/
a
c
e
t
o
n
i
t
r
i
l
e
N
G
N
G
N
G
N
G
E
x
t
i
n
c
t
i
o
n
c
o
e
f
ﬁ
c
i
e
n
t
￿
D
e
v
e
l
o
p
e
d
a
m
u
l
t
i
f
u
n
c
t
i
o
n
a
l
i
m
a
g
i
n
g
p
r
o
b
e
f
o
r
N
I
R
F
i
m
a
g
i
n
g
,
d
e
l
i
v
e
r
y
o
f
D
F
O
t
o
t
u
m
o
r
c
e
l
l
s
,
a
n
d
p
o
t
e
n
t
i
a
l
c
h
e
l
a
t
i
o
n
o
f
r
a
d
i
o
m
e
t
a
l
s
[
3
8
]
E
x
/
E
m
s
p
e
c
t
r
a
￿
D
e
m
o
n
s
t
r
a
t
e
d
t
h
a
t
a
t
a
r
g
e
t
e
d
t
h
e
r
a
p
e
u
t
i
c
t
h
a
t
c
o
u
l
d
b
e
m
o
n
i
t
o
r
e
d
b
y
m
u
l
t
i
m
o
d
a
l
i
m
a
g
i
n
g
￿
D
e
v
e
l
o
p
e
d
a
n
o
v
e
l
p
l
a
t
f
o
r
m
f
o
r
o
p
t
i
m
i
z
a
t
i
o
n
o
f
m
u
l
t
i
m
o
d
a
l
i
m
a
g
i
n
g
a
g
e
n
t
s
I
n
t
e
g
r
i
n
α
v
β
3
D
O
T
A
C
y
p
a
t
e
I
n
-
1
1
1
0
.
1
M
N
a
O
A
c
5
.
5
8
0
°
C
,
1
h
A
d
m
i
n
i
s
t
e
r
e
d
N
G
N
G
￿
D
e
v
e
l
o
p
e
d
a
D
O
T
A
/
N
I
R
F
R
G
D
a
n
a
l
o
g
f
o
r
d
u
a
l
-
l
a
b
e
l
i
n
g
[
3
9
]
￿
A
m
o
u
n
t
:
1
4
0
–
8
0
0
p
m
o
l
￿
A
g
e
n
t
w
a
s
p
r
e
p
a
r
e
d
i
n
h
i
g
h
s
p
e
c
i
ﬁ
c
a
c
t
i
v
i
t
y
a
n
d
h
a
s
p
o
t
e
n
t
i
a
l
u
s
e
w
i
t
h
d
i
f
f
e
r
e
n
t
r
a
d
i
o
m
e
t
a
l
s
d
u
e
t
o
p
r
e
s
e
n
c
e
o
f
D
O
T
A
a
s
c
h
e
l
a
t
o
r
￿
A
c
t
i
v
i
t
y
:
1
.
5
–
7
.
4
M
B
q
￿
T
u
m
o
r
s
v
i
s
u
a
l
i
z
a
t
i
o
n
b
y
b
o
t
h
n
u
c
l
e
a
r
/
N
I
R
F
i
m
a
g
i
n
g
c
o
n
c
u
r
r
e
d
w
i
t
h
r
e
p
o
r
t
s
f
r
o
m
e
a
r
l
i
e
r
s
t
u
d
i
e
s
.
S
S
T
R
D
O
T
A
C
y
p
a
t
e
C
u
-
6
4
,
L
u
-
1
7
7
0
.
1
M
N
a
O
A
c
5
.
5
2
5
°
C
;
8
0
°
C
f
o
r
8
0
m
i
n
P
r
e
p
a
r
e
d
(
6
4
C
u
)
N
G
E
x
/
E
m
s
p
e
c
t
r
a
￿
D
e
v
e
l
o
p
e
d
a
d
u
a
l
-
l
a
b
e
l
e
d
S
S
T
R
t
a
r
g
e
t
i
n
g
a
g
e
n
t
f
o
r
n
u
c
l
e
a
r
/
N
I
R
F
i
m
a
g
i
n
g
[
4
6
]
￿
A
m
o
u
n
t
:
1
n
m
o
l
Q
u
a
n
t
u
m
y
i
e
l
d
(
p
e
r
f
o
r
m
e
d
a
f
t
e
r
c
o
l
d
-
l
a
b
e
l
i
n
g
)
￿
U
t
i
l
i
z
e
d
t
h
e
r
a
p
e
u
t
i
c
r
a
d
i
o
n
u
c
l
i
d
e
s
i
n
m
u
l
t
i
-
m
o
d
a
l
m
o
n
o
m
o
l
e
c
u
l
a
r
i
m
a
g
i
n
g
a
g
e
n
t
(
M
O
M
I
A
)
d
u
a
l
-
l
a
b
e
l
i
n
g
s
t
r
a
t
e
g
y
￿
A
c
t
i
v
i
t
y
:
1
2
.
3
M
B
q
￿
F
l
u
o
r
e
s
c
e
n
t
p
r
o
p
e
r
t
i
e
s
w
e
r
e
r
e
t
a
i
n
e
d
a
f
t
e
r
l
a
b
e
l
i
n
g
w
i
t
h
m
e
t
a
l
.
A
d
m
i
n
i
s
t
e
r
e
d
(
6
4
C
u
)
￿
E
x
c
e
l
l
e
n
t
a
g
r
e
e
m
e
n
t
b
e
t
w
e
e
n
t
h
e
o
p
t
i
c
a
l
a
n
d
r
a
d
i
o
c
h
e
m
i
c
a
l
b
i
o
d
i
s
t
r
i
b
u
t
i
o
n
d
e
m
o
n
s
t
r
a
t
e
s
t
h
e
u
t
i
l
i
t
y
o
f
M
O
M
I
A
p
l
a
t
f
o
r
m
￿
A
m
o
u
n
t
:
1
2
p
m
o
l
￿
A
c
t
i
v
i
t
y
:
0
.
2
M
B
q
M
M
P
D
O
T
A
I
R
D
y
e
8
0
0
C
W
C
u
-
6
4
0
.
1
M
N
a
O
A
c
6
5
0
°
C
,
1
h
P
r
e
p
a
r
e
d
Y
e
s
N
G
￿
A
p
p
l
i
c
a
t
i
o
n
o
f
m
u
l
t
i
m
o
d
a
l
i
m
a
g
i
n
g
t
o
d
e
t
e
c
t
n
e
w
b
o
n
e
f
o
r
m
a
t
i
o
n
i
n
v
i
v
o
[
6
4
]
￿
A
m
o
u
n
t
:
6
–
3
5
n
m
o
l
￿
P
E
T
/
N
I
R
F
i
m
a
g
i
n
g
s
e
r
v
e
d
a
s
a
n
e
a
r
l
y
i
n
d
i
c
a
t
o
r
o
f
n
e
w
b
o
n
e
f
o
r
m
a
t
i
o
n
p
r
i
o
r
t
o
a
n
a
t
o
m
i
c
a
l
c
h
a
n
g
e
s
b
e
i
n
g
d
e
t
e
c
t
a
b
l
e
b
y
C
T
￿
A
c
t
i
v
i
t
y
:
3
7
–
7
4
M
B
q
A
d
m
i
n
i
s
t
e
r
e
d
￿
A
m
o
u
n
t
:
6
n
m
o
l
￿
A
c
t
i
v
i
t
y
:
7
.
4
M
B
q
M
M
P
D
O
T
A
I
R
D
y
e
8
0
0
C
W
G
a
-
6
8
0
.
1
M
N
a
O
A
c
4
9
5
°
C
,
1
0
m
i
n
P
r
e
p
a
r
e
d
Y
e
s
E
x
t
i
n
c
t
i
o
n
c
o
e
f
ﬁ
c
i
e
n
t
￿
D
e
v
e
l
o
p
e
d
a
d
u
a
l
-
l
a
b
e
l
e
d
n
u
c
l
e
a
r
/
N
I
R
F
i
m
a
g
i
n
g
a
g
e
n
t
u
s
i
n
g
g
e
n
e
r
a
t
o
r
-
p
r
o
d
u
c
e
d
6
8
G
a
[
4
9
]
￿
A
m
o
u
n
t
:
3
5
n
m
o
l
Q
u
a
n
t
u
m
y
i
e
l
d
(
p
e
r
f
o
r
m
e
d
a
f
t
e
r
r
a
d
i
o
l
a
b
e
l
i
n
g
)
￿
C
h
e
m
i
c
a
l
,
r
a
d
i
o
c
h
e
m
i
c
a
l
,
a
n
d
o
p
t
i
c
a
l
s
t
a
b
i
l
i
t
y
w
a
s
s
h
o
w
n
￿
A
c
t
i
v
i
t
y
:
5
5
.
5
M
B
q
￿
I
n
v
i
v
o
P
E
T
/
N
I
R
F
i
m
a
g
i
n
g
d
e
m
o
n
s
t
r
a
t
e
d
f
e
a
s
i
b
i
l
i
t
y
o
f
u
s
i
n
g
6
8
G
a
w
i
t
h
N
I
R
F
a
s
a
d
u
a
l
-
l
a
b
e
l
i
n
g
s
t
r
a
t
e
g
y
f
o
r
p
e
p
t
i
d
e
s
o
r
s
m
a
l
l
m
o
l
e
c
u
l
e
s
A
d
m
i
n
i
s
t
e
r
e
d
￿
A
m
o
u
n
t
:
6
n
m
o
l
￿
A
c
t
i
v
i
t
y
:
7
.
4
M
B
q
I
n
t
e
r
l
e
u
k
i
n
-
1
1
r
e
c
e
p
t
o
r
-
α
D
T
P
A
I
R
7
8
3
I
n
-
1
1
1
0
.
1
M
N
a
O
A
c
N
G
2
5
°
C
,
3
0
m
i
n
A
d
m
i
n
i
s
t
e
r
e
d
N
G
E
x
/
E
m
s
p
e
c
t
r
a
￿
A
p
p
l
i
e
d
d
u
a
l
-
l
a
b
e
l
i
n
g
s
t
r
a
t
e
g
y
f
o
r
n
u
c
l
e
a
r
/
N
I
R
F
i
m
a
g
i
n
g
o
f
I
L
-
1
1
R
α
w
i
t
h
o
u
t
a
l
t
e
r
i
n
g
t
a
r
g
e
t
i
n
g
c
a
p
a
b
i
l
i
t
y
o
f
p
e
p
t
i
d
e
[
5
0
]
￿
A
m
o
u
n
t
:
2
n
m
o
l
￿
1
1
1
I
n
c
h
e
l
a
t
i
o
n
s
h
o
w
e
d
n
o
q
u
e
n
c
h
i
n
g
o
f
ﬂ
u
o
r
e
s
c
e
n
c
e
￿
P
r
e
l
i
m
i
n
a
r
y
i
m
a
g
i
n
g
b
y
o
p
t
i
c
a
l
a
n
d
n
u
c
l
e
a
r
m
e
t
h
o
d
s
w
e
r
e
c
o
n
s
i
s
t
e
n
t
268 A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agentslisting of the dual-labeled peptide tracers that emit in the
NIR wavelength range of 750–900 nm and have been
investigated preclinically. Predominantly, dual-labeling
efforts build upon known radiotracers by utilizing estab-
lished molecular targeting moieties, BFCAs, and radio-
labeling schemes, and appending these with NIRF dyes.
The majority of targets evaluated are based on well-
characterized radiopeptides that target αvβ3 integrins,
SSTRs, and matrix metalloproteinases (MMPs) [34–36].
The dependence of solid tumors on increased blood
supply through new vessel formation has been studied non-
invasively with the αvβ3 integrin-targeting peptide sequence
Arg-Gly-Asp (RGD). Houston et al. prepared a dual-labeled
RGD agent using DTPA, IRDye 800CW, and
111In and
demonstrated the feasibility of combined nuclear/NIRF
imaging following administration of a dual-labeled agent
[37]. They also performed image quality assessment of an
optical intensiﬁed charge-coupled device-based camera
imaging in comparison with nuclear imaging. Their ﬁndings
demonstrated an approach for cross-validating NIRF imag-
ing platforms with nuclear imaging, an essential component
for clinical translation of functional planar NIR imaging that
may be achieved through dual-labeling strategies. Ye et al.
developed a multifunctional RGD imaging probe for NIRF
imaging, delivery of desferrioxamine to tumor cells, and
potential chelation of radiometals [38]. They provided
evidence of a targeted therapeutic that could be monitored
by multimodal imaging and in doing so, developed a novel
platform for optimization of multimodal imaging agents. In a
study by Edwards et al., the RGD peptide was conjugated
with cypate and DOTA, and radiolabeled with
111In with
high-speciﬁc activity for SPECT imaging [39]. They
prepared a DOTA/NIRF RGD analog for dual-labeling
which has potential use with different radiometals due to
presence of DOTA as the chelator. The authors also reported
high binding afﬁnity for the αvβ3 integrin with receptor-
speciﬁc binding in vitro, along with excellent agreement
between the optical and nuclear imaging results in mice.
The SSTR has been actively investigated in the imaging
ﬁeld due to its overexpression in several types of neuroen-
docrine tumors and potential as a biomarker for diagnosis
and therapy. Discovery of the receptor antagonist octreotide
[40], and its subsequent development into an imaging agent,
has been used for SPECT [41, 42] and PET imaging [43–45]
of NETs. Edwards and colleagues prepared a dual-labeled
SSTR agent for PET/NIRF imaging by attaching the NIRF
dye cypate to the C-terminus of DOTA-octreotate and
radiolabeling with
64Cu [46]. Their agent for nuclear/NIRF
imaging was developed alongside efforts to utilize therapeu-
tic radionuclides in a multimodal monomolecular imaging
agent (MOMIA) dual-labeling strategy. Characterization of
spectral properties showed that ﬂuorescent properties were
retained after labeling with metal. Although the in vivo images
did not reﬂect the in vitro results, the authors did observe
excellent agreement between the optical and radiochemical
biodistribution showing the promise of the MOMIA platform.
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A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agents 269Expression of MMP-9 during remodeling of the extracellular
matrix has been shown to be a potential biomarker for
heterotopic ossiﬁcation [47]. Rodenberg et al. developed an
MMP-9-targeting peptide conjugated with DOTA and IRDye
800CW, followed by labeling with
64Cu for early detection of
new bone formation by PET [48]. This study demonstrated the
application of multimodal imaging to detect new bone formation
in vivo and demonstrated the utility of PET/NIRF imaging for
earlydetection ofmolecularchangespriortoanatomical changes
detected by computed tomography. A follow-up study using the
same bioconjugate resulted in a dual-labeled nuclear/NIRF
imaging agent with generator-produced
68Ga and provided
detailed characterization of chemical, radiochemical, and optical
properties of a dual-labeled imaging agent [49]. Multimodal
imaging demonstrated the feasibility of using
68Ga with NIRF as
a dual-labeling strategy for peptides or small molecules, though
modiﬁcations to improve bioactivity of the agent are needed.
Several other targets have been evaluated with multimodal
peptide agents. An interleukin-11 receptor-α targeting peptide
was dual-labeled using an
111In-DTPA chelate and IR-783 [50].
The authors reported no quenching of ﬂuorescence after
radiolabeling, demonstrating a promising approach for
SPECT/NIRF imaging. In a study by Lee et al., multimodal
imaging of caspase-3 activity was conducted by using a
combined activatable and radiolabeled multimodality molecular
probe, demonstrating potential uses of multimodal imaging
agents activated by enzymatic cleavage [51]. Although the
targeting agent was not peptide-based, it is noteworthy to
include a study where a SPECT/NIRF probe based on
bisphosphonate was used to detect breast cancer microcalciﬁca-
tions [52].
99mTc labeling effects on the spectral properties of
IRDye 800CW were assessed and the authors showed promis-
ing results which demonstrated nearly identical total body
clearance compared to the nuclear “gold standard”
99mTc-MDP.
With the exception of the
68Ga MMP-9 targeting probe
[49], dual-labeled peptide imaging agents have used longer-
lived radiometals with half-lives ranging from 6 h to nearly
1 week. This approach is effective in the early stages of agent
development to (1) enable longitudinal imaging at early and
delayed time points, (2) monitor biodistribution, clearance
routes, agent stability, and (3) determine the optimal time point
for imaging; however, it does not take full advantage of the
favorable PK properties of peptides for early (i.e., 1–2h )
imaging. Direct comparison of a dual-labeled MMP peptide
with
64Cu and
68Ga showed faster clearance of the
68Ga
complex from blood and other background tissues, enabling
imaging at 1 h. Thus, further examination of
68Ga analogs for
dual labeling is warranted and may offer an efﬁcient route for
agent development and pharmacological evaluation.
Signiﬁcance of Characterizing Optical
Properties
In order to maximize the performance of dual-labeled
conjugates for multimodality imaging, the selection of an
optimal radionuclide/dye combination is required. Moreover,
characterization of dye performance in response to radio-
labeling would help guide efﬁcient development of novel dual-
labeled imaging probes and help expand the utility of nuclear
imaging agents to include intraoperative guidance. Yet despite
theprogressondual-labeledagentdevelopment,there has been
little effort to catalog the ﬂuorescence intensity of NIRF dyes
under the various radiolabeling conditions. Such characteriza-
tion is performed by evaluation of excitation/emission spectra,
absorption cross section, quantum efﬁciency, and in some
cases, ﬂuorescent lifetime. Spectral analyses have primarily
been reported on dual conjugates (i.e., agent with NIRF dye
andBFCA,but noradiometal),butneglect the effectsofmetals
(or radiometals) on optical properties.
Although the majority of dual-labeling approaches ex-
hibit some overlap with regard to selection of NIRF dyes,
BFCAs, and radiometals, to date there are no standardized
methods for assessing product quality for a dual-labeled
agent. Table 4 shows suggested characterization steps that
can be employed. A strategy to evaluate the chemical
integrity of the agent by HPLC, along with detailed analysis
of the spectral properties by ﬂuorometry before and after
radiolabeling, would give a good indication of the overall
stability of the agent and potentially establish speciﬁcations
that could be used for translational studies. Such analyses
could be performed before and after radiolabeling for
comparative purposes in addition to standard quality control
experiments for radiotracers such as radio-thin-layer chro-
matography (radio-TLC) or radio-HPLC. In the case of
mAbs, the randomness of the conjugation reactions necessitates
additional characterization to determine (1) immunoreactivity
Table 4. Analytical methods for characterizing dual-labeled agents
Assay type Targeting vector
Peptide-based mAb-based
Chemical
Characterization/
puriﬁcation
RP-HPLC SEC-HPLC
Mass spectrometry Mass spectrometry
NMR SDS-PAGE
Stability studies Stability studies
Biological
Characterization Conﬁrm bioactivity/
afﬁnity
Assess
immunoreactivity
Radiochemical
Characterization/puriﬁcation RP-HPLC SEC-HPLC
Radio-TLC Radio-TLC
Solid-phase
extraction (RP)
SEC columns
Chelators
quantiﬁcation
Radiometal quenchers
Optical
Characterization RP-HPLC SEC-HPLC
Spectral properties Spectral properties
Dye/protein ratio
RP-HPLC reversed phase high-performance liquid chromatography,
SEC-HPLC size-exclusion reversed phase high-performance liquid
chromatography, NMR nuclear magnetic resonance, radio-TLC radio-thin-
layer chromatography, SDS-PAGE sodium dodecyl sulfate polyacrylamide gel
electrophoresis
270 A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agentsby a modiﬁed Lindmo assay [33]o rN I R - b a s e dﬂow cytometry,
(2) dye/protein ratio by spectroscopy, and (3) BFCA/protein
ratio using a carrier-added radiolabeling method [53].
The lack of validating NIRF dye stability and optical
properties under radiolabeling conditions may be attributed to
failed, ﬁrst clinical studies which combined
99mTc and ICG for
LN staging. In a study of sentinel LN mapping in breast cancer
by Sevick-Muraca et al., HPLC analysis of ICG following
additionto pertechnetate showed instability of the dye, resulting
inalossofﬂuorescenceopticalproperties[6]duepresumablyto
the instability of ICG at lower pH [54]. While gamma
scintigraphy and blue dye (but not NIRF) enabled efﬁcient
detection of sentinel LNs, it was only when ICG was injected
separately that LNs and lymphatic structures were readily
visualized by NIRF. Recently, Buckle et al. reported on a
multimodal formulation using albumin colloids that sequester
ICG in high concentrations and likely prevent the stacking of
molecules and subsequent quenching of the dye, ultimately
resulting in more stable complexes with higher target-to-
background ratios [55]. While addressing the quenching issues,
the effects of pH and radiolabeling formulation on the optical
properties of ICG have yet be determined for the nanocolloid
formulation and are warranted given the known stability
concerns with ICG. Nonetheless, the formulation was evaluated
in patients and demonstrated the effectiveness of a hybrid
multimodal agent which combined ﬂuorescent ICG and human
serum albumin-based
99mTc-radiocolloid [56]. Continued
efforts to improve the formulation of dual-labeled agents are
neededtoconserve(orenhance)NIRFproperties,permithighly
sensitive detection of the agent following microdose adminis-
tration, and facilitate their translation into clinical practice.
Comparison of NIRF Dyes
under Dual-Labeling Conditions
Spectral Properties in Nonradioactive Labeling
Schemes
The commercially available NIRF dyes listed in Table 1
were obtained as lyophilized powders and stored at −20°C
with protection from light. Nonradioactive-labeling condi-
tions were selected based on the conditions in Table 5 as
follows: (1)
99mTc: PBS, pH 7.4, add 50 μLo fS n C l 2 (2 mg/ml
0.05 M HCl); (2)
64Cu: 0.1 M NaOAc, pH 6; (3)
111In: 0.2 M
NaOAc, pH 6; and (4)
68Ga: 1.25 M NaOAc, pH 4. Figure 4
shows the experimental design used. All solutions were kept at
room temperature and evaluated within 1 h of preparation.
Preparation of Radioactive Solutions
Dyes which showed greater ﬂuorescence intensity (i.e.,
extinction coefﬁcient (EC), QY) than ICG proceeded to
testing with radioactive solutions.
64CuCl2 was obtained
from Washington University (St. Louis, MO, USA) and
diluted with 0.1 N NaOAc (pH 6). Radioactivity (11.1 MBq)
was added to solutions of dye in the same buffer with a ﬁnal
volume of 300 μL. Reactions were heated at 50°C for
30 min followed by dilution to a 6 μM ﬁnal concentration
with 10–15 mL water. Samples were used within 1 h for
optical property assessment.
To test the effect of
68Ga on optical properties, lyophilized
dyes were reconstituted in 200 μL 1.25 M NaOAc at
pH 4.
68Ga was eluted in-house from a commercially
available
68Ge/
68Ga generator (Eckert & Ziegler, Berlin,
Germany) as previously described [49]. To each dye solution,
increasing activities of
68Ga (22.2, 59, and 152 MBq) were
added in eluate volumes of 0.2, 0.5, and 1.2 mL, respectively.
Samples were heated at 95°C for 10 min to simulate
68Ga-
labeling conditions commonly used for peptide tracers.
Samples were diluted to 6 μM with water or 1.25 M NaOAc
( p H4 )a n du s e dw i t h i n1hf o ro p t i c a lp r o p e r t ya s s e s s m e n t .
Assessment of Spectral and Chemical Properties
Absorbance of all solutions was measured at 785 nm (DU-
800 Spectrophotometer, Beckman Coulter, Brea, CA, USA)
to obtain an extinction cross section from the slope of
absorbance versus dye concentration. The ﬂuorescent prop-
erties of the solutions were evaluated using a Fluorolog Tau-3
Table 5. Conditions for conventional radiometal chelation schemes
Radiometal/chelators Reaction buffer pH Heating temperature (°C)
Tc-99 m
NxS4−x Saline 7–82 5
Organometallic tricarbonyl Saline 7.4 60–100
Cu-64
DOTA 0.1 M acetate 5.5–6.5 25–50
TETA 0.1 M acetate 5.5 25
CB-TE2A 0.1 M acetate 8.0 95
NODAGA 0.1 M acetate 6–82 5
In-111
DTPA 0.1–1.0 M acetate 5–62 5
DOTA 0.1–1.0 M acetate 5–62 5 –95
Ga-68
DOTA 0.1–1.25 M acetate 3.0–4.5 95
NOTA, NODAGA 0.1–1.0 M acetate 3.5–4.5 25–40
A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agents 271spectroﬂuorometer (Horiba Jobin Yvon, Edison, NJ, USA) at
Ex/Em=785/830 nm to compute QY (f) using the method of
Williams et al. [57], with ICG (f=0.016) at Ex/Em=785/
830 nm serving as a standard [58]. Relative brightness (RB) of
each NIRF dye relative to ICG was computed by dividing the
product of EC and QY with that of ICG. Chemical stability of
selected dye solutions (both radioactive and nonradioactive)
wasevaluatedbyanalyticalHPLCaspreviouslydescribed[49].
Stability of nonradioactive samples in water was measured at 0,
4, 6, 12, and 24 h after preparation, while
68Ga samples were
analyzed at 0, 2, and 4 h post-mixing. Each dye showed
excellent chemical stability in water over the time points
investigated as no new peaks were detected on UV (280 nm)
or ﬂuorescence channels. Similarly, no radiolytic or breakdown
products were observed by HPLC following incubation with
68Ga on UV (280 nm) or ﬂuorescence channels.
Roadmap for Efﬁcient Design
and Implementation of Dual-Labeled
Agents
The ability of NIRF dyes to withstand various radiolabeling
conditions and maintain optical integrity is critical for the
developmentandadvancementofdual-labeledimagingagents.
Comparison of several commercially available NIRF dyes in
water showed that each dye, with the exception of Cy7 and IR-
783, was signiﬁcantly brighter than ICG (Fig. 5). CF790 and
Alexa Fluor 790 were the brightest of all dyes tested, both with
a ∼4.5-fold increase in RB compared to ICG. IRDye 800CW
hasbeenextensivelyusedbyourgroupandothers,andshowed
excellent optical properties with a threefold increase in RB
compared to ICG. It is noteworthy to mention that our spectral
analyses were conducted using parameters optimized for ICG;
thus, dyes which exhibited low ﬂuorescence under these
conditions would clearly beneﬁt from tuning of factors such
as Ex/Em wavelengths and ﬁlter settings to better demonstrate
their utility in future studies.
Radiolabeling schemes incorporate a wide array of
buffers, pH ranges, and heating temperatures, all of which
can impact spectral properties of NIRF dyes. Nonradioactive
radiolabeling schemes of the four most prevalent radiometals
used in nuclear imaging were applied to the NIRF dyes as a
preliminary step to assess potential dye/radiometal combi-
nations. CF790 and Alexa Fluor 790 were superior under all
buffer conditions tested and exhibited no signiﬁcant decrease
in RB under
99mTc conditions (Fig. 6) compared to water
controls. The harshness of reaction conditions (
68Ga9
111In9
64Cu9
99mTc), primarily resulting from differences in pH and
buffer concentrations, impacted RB for both CF790 and
Alexa Fluor 790, while IRDye 800CW ﬂuorescence
remained relatively unchanged in different buffers. CF770
also showed stable ﬂuorescent signal in each buffering
system, though its RB was lower than IRDye 800CW. As
was the case with water, Cy7 was not as bright as ICG. The
data showed distinct differences between dye performance,
while also depicting certain dye/radiometal combinations
that may preferentially conserve optical properties to yield
more sensitive imaging agents.
The four radiometals examined have distinct radioactive
emissions (
99mTc=140 keV γ;
64Cu=1.7 MeV β
+, 578 keV
β
−;
111In=171 and 245 keV γ, Auger electrons;
68Ga=
1.9 MeV β
+) which have been exploited in biomedical
applications. Spectral analysis of dye–metal complexation
Fig. 4. Experimental design for characterization of NIRF dyes in water, buffers, and radioactive solutions.
Fig. 5. Relative brightness of various NIRF dyes in water.
Samples were normalized with ICG (φ=0.016) at 785 nm
excitation and 830 nm emission as a standard.
272 A. Azhdarinia et al.: Radiolabeling of NIRF Imaging Agentshas shown that metal ions can impact the optical stability of
dual-labeled agents through the formation of charge transfer
complexes between the metals and the ﬂuorophore [59],
though differences in chemical structure of dyes must be
taken into account. To test the effects of clinically used
radioactive metals on the NIRF dyes, we selected
64Cu and
68Ga due to their varying emissions, prevalence of use in
molecular imaging, and the overall clinical signiﬁcance of
PET imaging.
64Cu reduced the RB of each dye compared to
water controls with varying degrees of tolerance for 0.1 M
NaOAc at pH 6 and the 30 min heating step conducted at
50°C (RB: Alexa Fluor 7909CF7909IRDye 800CW9
CF770; Fig. 7). Assessment of optical properties with
68Ga
was performed under harsher conditions (1.25 M NaOAc at
pH 4, heating at 95°C for 10 min) to represent a commonly
used clinical formulation [60]. Also, three activity levels were
examined to reﬂect typical preparation of a dual-labeled probe
for an in vitro study (low activity, 22.2 MBq), an in vivo
imaging study (medium activity, 59 MBq), and a proposed
human study (high activity, 152 MBq). Each
68Ga experiment
had similar ﬁndings with the RB of CF7909Alexa Fluor 7909
IRDye 800CW9CF770 and a dose-dependent reduction in RB
was observed.
While the empirical data provide evidence on dye perfor-
mance, several other considerations must be taken into account
before selecting a certain NIRF dye for agent development.
First, the dyes evaluated were of varying MW, and thus can
have signiﬁcantly different effects on the PK proﬁle of a
multimodal agent. CF790 showed excellent optical properties
under all test conditions including with
68Ga, making it an
excellent candidate for dual-labeling; however, its size of
3,200 Da may prohibit its use with peptides due to concerns
over a potential decrease in binding afﬁnity resulting from
steric effects of the bulky dye, altered biodistribution with
increased blood circulation, and higher levels of hepatobiliary
clearance. A more practical application of CF790 may be in its
use with mAbs or engineered mAb fragments which can
tolerate such an increase in MW without signiﬁcant perturba-
tion of binding, assuming the pharmacophore is not disrupted
during the labeling process. Alternatively, Alexa Fluor 790 is a
much smaller NIRF dye (MW 1,750 Da) and exhibited
comparable optical characteristics to CF790, making it more
amenable to use with peptides. A factor which may limit the
use of Alexa Fluor 790 is its exorbitant cost, which is greater
than tenfold higher than other dyes at the time of publication,
and may serve as an obstacle when considering the future
productionundergoodmanufacturingpractice(GMP)required
for safety and toxicity testing en route to clinical translation.
Also, the chemical structures of CF770, CF790, and Alexa
Fluor 790 were not readily available, with vendors only
indicating that the dyes exist as NHS-esters for coupling
reactions. The improved optical stability of these dyes may be
attributed to the presence of modiﬁed aromatic groups,
polymethine groups, or groups for improving solubility,
though we can only speculate until more information on their
chemical compositions are revealed. The lack of structural
information also complicates agent development by limiting
the ability to predict potential changes in PK which directly
affect biodistribution and dosimetry measurements, criteria
w h i c hn e e dt ob ew e l l - d e ﬁned for translation. In contrast,
IRDye 800CW has been well-characterized in both mAb and
peptide-targeting schemes [23, 28, 33, 37, 61–65]a n d
demonstrated acceptable ﬂuorescence under all conditions.
IRDye 800CW (MW 1091.1) is well-suited for peptide
labeling and, with its published chemical structure, PK
modulation strategies can be employed as needed into solid-
phase peptide synthesis to reduce potential changes resulting
from increased lipophilicity or circulation time.
Ideally, a speciﬁc NIRF dye/radionuclide combination
can be designated as “best” for a particular use. However,
the cost of reagents, access to radioisotopes, and variability
Fig. 6. Relative brightness of various NIRF dyes in buffers.
Samples were normalized with ICG (φ=0.016) at 785 nm
excitation and 830 nm emission as a standard.
Fig. 7. Relative brightness of various NIRF dyes in radioac-
tive solutions of
64Cu (11.1 MBq) and
68Ga. Three different
activity levels of
68Ga were used: low=22.2 MBq, med=
59 MBq, high=152 MBq. Samples were normalized with ICG
(φ=0.016) at 785 nm excitation and 830 nm emission as a
standard.
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practicality of such an approach within diverse research
environments. Moreover, unlike full-length mAbs where
overall agent size is quite uniform, the size of peptide-based
targeting agents is highly variable and will dictate the NIRF
dye selected, which then in turn impacts PK, and ultimately
determines which radioisotope is best suited to obtain high
signal-to-noise ratios during imaging. We envision our
results serving as an impetus to stimulate characterization
of the multitude of other NIRF dyes which have applications
in dual-labeling. Complementary efforts by imaging scien-
tists may lead towards the assembly of a robust database of
NIRF dye/radionuclide interaction and ultimately establish a
dual-labeling toolkit for smart agent design.
Future Directions
Clinical nuclear imaging stands to beneﬁt greatly from the
introduction of improved NIRF dyes. Dual-labeled agents
may allow a single targeting moiety to be used throughout
the patient care process for diagnosis, staging, treatment
planning, surgical guidance, therapeutic monitoring, and
validation of histological ﬁndings. Since molecularly tar-
geted, chelator-based multimodal probes have yet to be used
in humans, exact speciﬁcations will need to be deﬁned for
batch release and may initially follow guidelines set forth for
conventional chelator-based radiotracers which are outlined
in the Food and Drug Administration (FDA) guidance
documents for GMP manufacturing of imaging agents [66].
Along with a better understanding of the capabilities of
NIRF dyes, continued testing in preclinical studies is needed
to compare the sensitivity and speciﬁcity of NIRF and
nuclear imaging for potential clinical applications. The
ﬁndings should build upon the existing knowledge and
make signiﬁcant strides towards validating multimodal
imaging platforms for clinical use. Innovative chemistry
strategies to combine chelators and NIRF dyes into a single
“reactive” unit have been shown and offer great promise to
simplify agent synthesis and broaden the use of multimodal
probes [67–70]. Given the importance of mAb-based
targeting approaches, such platforms may help mitigate the
loss of immunoreactivity that can occur following multistep
conjugations at random sites on mAbs or mAb fragments.
As dual-labeled agents proceed towards human testing,
certain challenges must be addressed including detailed
toxicological analysis to demonstrate safety and determine
dosing capabilities. Accordingly, bulk amounts of probe will
be needed for such studies, thus an efﬁcient and scalable
GMP manufacturing process will need to be developed by
dye manufacturers yet still be affordable to researchers. FDA
approval may be required on multiple levels as novel NIRF
dyes are considered new chemical entities and will require
their own rigorous preclinical characterization in addition to
the requirements for NIRF dye conjugates. Reports by
manufacturers such as LI-COR Biosciences indicate that
IRDye 800CW is navigating the regulatory process and may
serve as a benchmark for other dye developers [63].
Other alternatives for dual-labeling strategies other than
those described above employ isotopic substitution of a
radionuclide either directly onto a NIRF dye, or on a protein,
sugar, or macromolecule that is conjugated to NIRF dye.
Although potentially more cumbersome than chelation
chemistry, opportunities for dual-labeled agents with isoto-
pic substitution may be possible. For example, Tsing and
colleagues [71] combined a boronate trap for ﬂuoride on an
NIRF dye with an activated ester for bioconjugation. As
proof of concept, the entity was conjugated to Lymphoseek,
a mannosylated 16 kDa dextran conjugate that was previ-
ously developed for radiolabeling with
99mTc for sentinel
LN mapping [72]. Facile incorporation of
18F into the NIRF-
labeled Lymphoseek enables PET/NIRF imaging, yet NIRF
optical properties and agent performance remain to be
evaluated following radiolabeling. Given that positron
annihilation requires interaction with electrons that may also
be associated with the electron dense region of a ﬂuoro-
phore, consideration of the impact of the radioactive decay
upon ﬂuorescent properties is warranted.
The objective of this review was to provide a detailed
description of the components of dual-labeled nuclear/NIRF
imaging probes and evaluate combinations of dyes with key
radiometals in nuclear imaging. Ultimately, imaging
researchers will have the ability to select proven components
from a “toolkit” for customized multimodal agent design,
potentially improving imaging and translational capabilities.
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